Literature DB >> 9307560

Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy.

M E Helewa1, R F Burrows, J Smith, K Williams, P Brain, S W Rabkin.   

Abstract

OBJECTIVES: To provide Canadian physicians with a standard definition of hypertension in pregnancy, recommendations for laboratory investigations and tests for the assessment and management of hypertensive disorders in pregnancy, and a classification of such disorders. OPTIONS: To improve or not improve Canadian uniformity and standardization in the investigation and classification of hypertensive disorders in pregnancy. OUTCOMES: 1) Accuracy, reliability and practicality of diagnostic clinical criteria for hypertensive disorders in pregnancy. 2) Laboratory tests useful to determine severity and prognosis of disorders as measured by maternal and neonatal adverse outcomes. 3) A classification of disorders for use by Canadian physicians to facilitate uniformity and diffusion of research through a common language. EVIDENCE: Articles on hypertensive disorders in pregnancy published from 1966 to 1996, retrieved through MEDLINE search, related to definitions, tests, diagnostic criteria and classification, as well as documents on diagnosis and classification from authorities in the United States, Europe and Australia and from special interest groups. VALUES: High priority was given to the principle of preventing adverse maternal and neonatal outcomes through the provision of diagnostic criteria for severity and prognosis and through dissemination of reliable and pertinent information and research results using a common language. BENEFITS, HARMS AND COST: Higher degree of vigilance in diagnosing hypertensive disorders in pregnancy, allowing for earlier assessment and intervention, and more efficient dissemination of comparative information through common language. No harm or added cost is perceived at this time. RECOMMENDATIONS: (1) A diastolic blood pressure of 90 mm Hg or more should be the criterion for a diagnosis of hypertension in pregnancy and should trigger investigation and management. Except for very high diastolic readings (110 mm Hg or more), all diastolic readings of 90 mm Hg or more should be confirmed after 4 hours. (2) A regularly calibrated mercury sphygmomanometer, with an appropriate-sized cuff, is the instrument of choice. A rest period of 10 minutes should be allowed before taking the blood pressure. The woman should be sitting upright and the cuff positioned at the level of the heart. (3) Both Korotkoff phase IV and V sounds should be recorded, but the phase IV sound should be used for initiating clinical investigation and management. (4) A urine protein level of more than 0.3 g/d should be the criterion for a diagnosis of proteinuria; 24-hour urine collection should be the standard method for determining proteinuria. (5) Edema and weight gain should not be used as diagnostic criteria. (6) Hypertensive disorders diagnosed during pregnancy should be classified as pre-existing hypertension; gestational hypertension with or without proteinuria; pre-existing hypertension with superimposed gestational hypertension with proteinuria; and unclassifiable antenatally but final classification 42 days after delivery. VALIDATION: Except for expert opinions and reviews solicited for this project, these recommendations need to be field tested and validated in Canada. Guidelines endorsed by the Canadian Hypertension Society and the Society of Obstetricians and Gynaecologists of Canada.

Entities:  

Mesh:

Year:  1997        PMID: 9307560      PMCID: PMC1228113     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  74 in total

Review 1.  Hypertension in pregnancy.

Authors:  F G Cunningham; M D Lindheimer
Journal:  N Engl J Med       Date:  1992-04-02       Impact factor: 91.245

2.  Recording diastolic blood pressure in pregnancy.

Authors:  M A Brown; J A Whitworth
Journal:  BMJ       Date:  1991-07-13

3.  Umbilical artery resistance index as a screening test for fetal well-being. II: Randomized feasibility study.

Authors:  G J Hofmeyr; R Pattinson; D Buckley; J Jennings; C W Redman
Journal:  Obstet Gynecol       Date:  1991-09       Impact factor: 7.661

Review 4.  Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia.

Authors:  K G Perry; J N Martin
Journal:  Clin Obstet Gynecol       Date:  1992-06       Impact factor: 2.190

5.  Central hemodynamic observations in untreated preeclamptic patients.

Authors:  W Visser; H C Wallenburg
Journal:  Hypertension       Date:  1991-06       Impact factor: 10.190

6.  Proteinuria and its assessment in normal and hypertensive pregnancy.

Authors:  V S Kuo; G Koumantakis; E D Gallery
Journal:  Am J Obstet Gynecol       Date:  1992-09       Impact factor: 8.661

Review 7.  Indirect blood pressure measurement in pregnancy: Korotkoff phase 4 versus phase 5.

Authors:  A R Johenning; W M Barron
Journal:  Am J Obstet Gynecol       Date:  1992-09       Impact factor: 8.661

8.  Doppler flow velocity waveform analysis in high risk pregnancies: a randomized controlled trial.

Authors:  J P Newnham; M R O'Dea; K P Reid; D A Diepeveen
Journal:  Br J Obstet Gynaecol       Date:  1991-10

Review 9.  Diagnosis and management of chronic hypertension in pregnancy.

Authors:  B M Sibai
Journal:  Obstet Gynecol       Date:  1991-09       Impact factor: 7.661

Review 10.  Hypertension in pregnancy.

Authors:  B M Sibai
Journal:  Obstet Gynecol Clin North Am       Date:  1992-12       Impact factor: 2.844

View more
  44 in total

1.  Do acetylsalicylic acid and other antiplatelet drugs prevent preeclampsia?

Authors:  R Maharaj
Journal:  Can Fam Physician       Date:  2001-12       Impact factor: 3.275

Review 2.  Pathophysiology and maternal biologic markers of preeclampsia.

Authors:  Jacques Massé; Yves Giguère; Abdelaziz Kharfi; Joël Girouard; Jean-Claude Forest
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

3.  Preeclampsia - Aetiology, Current Diagnostics and Clinical Management, New Therapy Options and Future Perspectives.

Authors:  A-C Tallarek; B Huppertz; H Stepan
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-12       Impact factor: 2.915

Review 4.  Report of the Canadian Hypertension Society Consensus Conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy.

Authors:  J M Moutquin; P R Garner; R F Burrows; E Rey; M E Helewa; I R Lange; S W Rabkin
Journal:  CMAJ       Date:  1997-10-01       Impact factor: 8.262

5.  Analysis of F2-isoprostanes in plasma of pregnant women by HPLC-MS/MS using a column packed with core-shell particles.

Authors:  Jessica Larose; Pierre Julien; Jean-François Bilodeau
Journal:  J Lipid Res       Date:  2013-02-21       Impact factor: 5.922

6.  A Pregnant Woman with Lupus and Nephrotic-Range Proteinuria.

Authors:  Andrew S Bomback
Journal:  Clin J Am Soc Nephrol       Date:  2017-04-04       Impact factor: 8.237

7.  Plasma F2-isoprostane class VI isomers at 12-18 weeks of pregnancy are associated with later occurrence of preeclampsia.

Authors:  Jean-François Bilodeau; Shu Qin Wei; Jessica Larose; Karine Greffard; Vanessa Moisan; Francois Audibert; William D Fraser; Pierre Julien
Journal:  Free Radic Biol Med       Date:  2015-05-19       Impact factor: 7.376

8.  Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.

Authors:  R D Feldman; N R Campbell; P Larochelle
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

9.  1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

Authors:  R D Feldman; N Campbell; P Larochelle; P Bolli; E D Burgess; S G Carruthers; J S Floras; R B Haynes; G Honos; F H Leenen; L A Leiter; A G Logan; M G Myers; J D Spence; K B Zarnke
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

Review 10.  The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies.

Authors:  Marc A Rodger; Marisol T Betancourt; Peter Clark; Pelle G Lindqvist; Donna Dizon-Townson; Joanne Said; Uri Seligsohn; Marc Carrier; Ophira Salomon; Ian A Greer
Journal:  PLoS Med       Date:  2010-06-15       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.